Skip to content
value.today
Histogenics Corp. logo

Histogenics Corp.

Total raised
$10 M
1 round on record
Latest round
$10 M
Dec 2013
First round on record
Dec 2013
Today
Went public
See the company page

Histogenics Corp. is listed today as Ocugen, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Histogenics Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2020$14 MPrivate placement after listing$10 to $50 million

Histogenics Corp.: Private sale, Apr 2020

Investors in this round

6 investors had bought by the notice of May 7, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Histogenics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel B Jorgensen · Executive Officer
  • Kelly B Beck · Executive Officer
  • Rasappa B Arumugham · Executive Officer
  • Sanjay B Subramanian · Executive Officer
  • Shankar Musunuri · Executive Officer, Director · Chief Executive Officer and Chairman
  • Vijay B Tammara · Executive Officer
  • Junge Zhang · Director
  • Kristen B Castillo · Director
  • Manish B Potti · Director
  • Prabhavathi B Fernandes · Director
  • Ramesh Kumar · Director
  • Suha B Taspolatoglu · Director
  • Uday B Kompella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “21,920,820 shares of common stock and $5.625 million in aggregate principal amount of promissory notes issued in exchange for outstanding Series A Warrants.”

Signed by Sanjay Subramanian, Cfo. Source: SEC Form D, newest notice filed May 7, 2020. Read the notice at the SEC.

equity, debtSEC
Sep 2016$30 MPrivate placement after listing$10 to $50 million

Histogenics Corp.: Private sale, Sep 2016

Investors in this round

20 investors had bought by the notice of Oct 12, 2016: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Histogenics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Gridley · Executive Officer, Director
  • David J. Gill · Director
  • Garheng Kong, M.D., Ph.D. · Director
  • John J. Johnson · Director
  • Jonathan J. Lieber · Director
  • Joshua Baltzell · Director
  • Kevin Rakin · Director
  • Michael Lewis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. LLC (CRD 375) · New York, New YorkSold in CA, CT, MN, NJ, NY, TX

Signed by Adam Gridley, Ceo. Source: SEC Form D, newest notice filed Oct 12, 2016. Read the notice at the SEC.

equity, optionsSEC
Dec 2013$10 MNo. 1$10 to $50 million

Histogenics Corp.: Raise no. 1, Dec 2013

Investors in this round

17 investors had bought by the notice of Jan 6, 2014: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Histogenics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $21 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Greenleaf · Executive Officer, Director
  • Garheng Kong, M.D., Ph.D · Director
  • John Johnson · Director
  • Joshua Baltzell · Director
  • Kevin Rakin · Director
  • Michael Lewis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Greenleaf, President. Source: SEC Form D, newest notice filed Jan 6, 2014. Read the notice at the SEC.

equitySEC
Jul 2012$38 MIssued in a merger or acquisition$10 to $50 million

Histogenics Corp.: Private sale, Jul 2012

Investors in this round

13 investors had bought by the notice of Nov 26, 2012: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Histogenics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $58 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin McArdle · Executive Officer
  • Patrick O'Donnell · Executive Officer, Director
  • Garheng Kong · Director
  • Joshua Baltzell · Director
  • Kevin Rakin · Director
  • Michael Lewis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “13 (a) and (b) include $6,250,000 attributed to the conversion of debt into shares of common stock and $2,786,647 attributed to the estimated value of the warrants.”
  • On a merger: “In connection with the offering, the Company merged with Histogenics Finance Corporation, a Delaware corporation, with the Company continuing as the surviving entity. Such merger was effected solely for the purpose of reorganizing the Company's capital.”

Signed by Kevin McArdle, CFO and Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Nov 26, 2012. Read the notice at the SEC.

equity, optionsSEC
May 2011$34 MIssued in a merger or acquisition$10 to $50 million

Histogenics Corp.: Private sale, May 2011

Investors in this round

15 investors had bought by the notice of May 26, 2011: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Histogenics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$34 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$1,000,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian J.B. Callahan · Executive Officer
  • Kevin McArdle · Executive Officer
  • Kirk J.B. Andriano · Executive Officer
  • Laurence J.B. Tarrant · Executive Officer
  • Patrick O'Donnell · Executive Officer, Director
  • Dominic J.B. Redfern · Director
  • Harry J.B. Rein · Director
  • Michael J.B. Lewis · Director
  • Patrick J.B. Fortune · Director
  • Philip J.B. Press · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Boston Equity Advisors LLC (CRD 103300) · Canton, MassachusettsSold in CT, GA, MA, NJ

Remarks in the notice

  • On fees: “The broker/dealer fees were paid only in connection with the business combination and not in connection with the subsequent financing.”
  • On the amounts: “The Total Amount Sold consists of the value of equity issued in a recapitalization and a business combination and debt issued in a financing of the combined businesses.”

Signed by Kevin McArdle, Chief Financial Officer. Source: SEC Form D, newest notice filed May 26, 2011. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Histogenics Corp. chose not to state its revenue in its newest notice of a funding round (May 2020).

    SEC Form D · May 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2020

That is all the official record says: Histogenics Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Histogenics Corp. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Histogenics Corp.
InvestorKindAmountRoundRoleSource
Kevin RakinPersonnot statednot statedHeld Series A and A-1 preferred stock, director (Form 3, 2014)SEC Form 3
Sofinnova Management VIII, L.L.C.Fund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Sofinnova Venture Partners VIII, L.P.Venture capitalnot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Split Rock Partners II, LPFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Split Rock Partners II Management, LLCFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Wilmslow Estates LtdCompanynot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 17 investors.

Largest shareholders today

Institutions holding Ocugen, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Histogenics Corp.
NameRoleNamed in
Daniel B JorgensenExecutive officerMay 2020
Kelly B BeckExecutive officerMay 2020
Rasappa B ArumughamExecutive officerMay 2020
Sanjay B SubramanianExecutive officerMay 2020
Shankar MusunuriChief Executive Officer and ChairmanMay 2020
Vijay B TammaraExecutive officerMay 2020
Adam GridleyExecutive officerOct 2016
Peter GreenleafExecutive officerJan 2014
Kevin McArdleExecutive officerNov 2012
Patrick O'DonnellExecutive officerNov 2012
Brian J.B. CallahanExecutive officerMay 2011
Kirk J.B. AndrianoExecutive officerMay 2011
Laurence J.B. TarrantExecutive officerMay 2011
Junge ZhangDirectorMay 2020
Kristen B CastilloDirectorMay 2020
Manish B PottiDirectorMay 2020
Prabhavathi B FernandesDirectorMay 2020
Ramesh KumarDirectorMay 2020
Shankar MusunuriChief Executive Officer and ChairmanMay 2020
Suha B TaspolatogluDirectorMay 2020
Uday B KompellaDirectorMay 2020
Adam GridleyDirectorOct 2016
David J. GillDirectorOct 2016
Garheng Kong, M.D., Ph.D.DirectorOct 2016
John J. JohnsonDirectorOct 2016
Jonathan J. LieberDirectorOct 2016
Joshua BaltzellDirectorOct 2016
Kevin RakinDirectorOct 2016
Michael LewisDirectorOct 2016
Garheng Kong, M.D., Ph.DDirectorJan 2014
John JohnsonDirectorJan 2014
Peter GreenleafDirectorJan 2014
Garheng KongDirectorNov 2012
Patrick O'DonnellDirectorNov 2012
Dominic J.B. RedfernDirectorMay 2011
Harry J.B. ReinDirectorMay 2011
Michael J.B. LewisDirectorMay 2011
Patrick J.B. FortuneDirectorMay 2011
Philip J.B. PressDirectorMay 2011

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.